Search
Now showing items 1-5 of 5
Future of advanced heart failure and mechanical support devices: A Cardiology-Cardiovascular Surgery Consensus Report
(TURKISH SOC CARDIOLOGY, 2016)
Heart failure is a progressive disease. A considerable number of patients eventually reach an advanced or terminal phase, in spite of developments in diagnostic procedure, alternative treatments that can slow progression, ...
Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study
(TURKISH SOC CARDIOLOGY, 2016)
Objective: The present objective was to determine frequency of Arginine389Glycine (Arg389Gly) and Cytochrome p450 2D6*10 (Cyp2D6*10) polymorphism in cases of heart failure-reduced ejection fraction (HFREF), and to evaluate ...
Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine
(SPRINGER, 2007)
Background Levosimendan is a relatively new cardiac inotropic agent with calcium sensitizing activity. This study was conducted to investigate the effects of levosimendan (L) and dobutamine (D) on renal function in patients ...
Relationship between functional capacity and socioeconomic status in a cohort of Turkish heart failure patients
(TURKISH SOC CARDIOLOGY, 2016)
Objective: New York Heart Association (NYHA) classification predicts prognosis for heart failure (HF) patients. Socioeconomic status (SES) has the potential to affect treatment strategy and disease course. The present ...
2016 ESC and ACC/AHA/HFSA heart failure guideline updates: Changes, similarities, differences, and unresolved isssues
(TURKISH SOC CARDIOLOGY, 2016)
…